| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
11,270,000 |
| Market
Cap: |
287.50(M) |
| Last
Volume: |
197,427 |
Avg
Vol: |
196,884 |
| 52
Week Range: |
$13.82 - $26.5 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile XOMA is a biotech royalty aggregator. Co. has a portfolio of economic rights to milestone and royalty payments associated with partnered pre-commercial therapeutic candidates. Co.'s portfolio was built through licensing its proprietary products and platforms from its discovery and development business, combined with acquisitions of rights to milestones and royalties.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
10,600 |
117,800 |
| Total Buy Value |
$0 |
$0 |
$183,361 |
$2,088,813 |
| Total People Bought |
0 |
0 |
2 |
3 |
| Total Buy Transactions |
0 |
0 |
10 |
21 |
| Total Shares Sold |
0 |
0 |
0 |
27,000 |
| Total Sell Value |
$0 |
$0 |
$0 |
$809,425 |
| Total People Sold |
0 |
0 |
0 |
2 |
| Total Sell Transactions |
0 |
0 |
0 |
2 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
• – – |
2013-06-28 |
4 |
OE |
$3.45 |
$1,955 |
D/D |
567 |
4,101 |
|
- |
|
| Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
• – – |
2013-06-18 |
4 |
AS |
$0.00 |
$0 |
D/D |
(6,000) |
3,534 |
|
- |
|
| Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
• – – |
2013-06-18 |
4 |
OE |
$2.36 |
$7,387 |
D/D |
3,130 |
9,534 |
|
- |
|
| Varian John |
Director and CEO |
• • – |
2013-06-17 |
4 |
AS |
$0.00 |
$0 |
D/D |
(10,000) |
60,079 |
|
- |
|
| Varian John |
Director and CEO |
• • – |
2013-06-17 |
4 |
OE |
$1.24 |
$12,400 |
D/D |
10,000 |
70,079 |
|
- |
|
| Scannon Patrick J Md Phd |
Exec. VP & CSO |
• • – |
2013-06-11 |
4 |
AS |
$0.00 |
$0 |
D/D |
(10,000) |
17,448 |
|
- |
|
| Scannon Patrick J Md Phd |
Exec. VP & CSO |
• • – |
2013-06-11 |
4 |
OE |
$1.69 |
$16,900 |
D/D |
10,000 |
27,448 |
|
- |
|
| Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
• – – |
2013-05-29 |
4 |
S |
$4.16 |
$7,476 |
D/D |
(1,797) |
6,404 |
|
- |
|
| Bowes William K Jr |
Director |
– • – |
2013-05-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,800 |
8,370 |
|
- |
|
| Wyszomierski Jack L |
Director |
– • – |
2013-05-28 |
4 |
OE |
$2.69 |
$7,532 |
D/D |
2,800 |
7,299 |
|
- |
|
| Walbert Timothy P |
Director |
– • – |
2013-05-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,800 |
7,299 |
|
- |
|
| Van Ness W Denman |
Director |
– • – |
2013-05-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,150 |
10,026 |
|
- |
|
| Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
• – – |
2013-05-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,667 |
8,201 |
|
- |
|
| 14159, L.p. |
Director |
– • • |
2013-05-23 |
4 |
A |
$0.00 |
$0 |
I/I |
25,200 |
489,039 |
|
- |
|
| Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
• – – |
2013-05-20 |
4 |
AS |
$0.00 |
$3,266 |
D/D |
(6,000) |
3,534 |
|
- |
|
| Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
• – – |
2013-05-20 |
4 |
OE |
$2.36 |
$1,853 |
D/D |
785 |
9,534 |
|
- |
|
| Varian John |
Director and CEO |
• • – |
2013-05-15 |
4 |
AS |
$0.00 |
$0 |
D/D |
(10,000) |
60,079 |
|
- |
|
| Varian John |
Director and CEO |
• • – |
2013-05-15 |
4 |
OE |
$1.24 |
$12,400 |
D/D |
10,000 |
70,079 |
|
- |
|
| Scannon Patrick J Md Phd |
Exec. VP & CSO |
• • – |
2013-05-14 |
4 |
AS |
$0.00 |
$0 |
D/D |
(10,000) |
17,448 |
|
- |
|
| Scannon Patrick J Md Phd |
Exec. VP & CSO |
• • – |
2013-05-14 |
4 |
OE |
$1.69 |
$16,900 |
D/D |
10,000 |
27,448 |
|
- |
|
| Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
• – – |
2013-04-18 |
4 |
AS |
$0.00 |
$0 |
D/D |
(6,000) |
8,749 |
|
- |
|
| Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
• – – |
2013-03-28 |
4 |
OE |
$3.32 |
$4,967 |
D/D |
1,498 |
14,749 |
|
- |
|
| Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
• – – |
2013-03-19 |
4 |
S |
$3.29 |
$22,997 |
D/D |
(6,990) |
13,251 |
|
- |
|
| Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
• – – |
2013-03-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,205 |
20,241 |
|
- |
|
| Scannon Patrick J Md Phd |
Executive Vice President |
• • – |
2012-12-31 |
5 |
A |
$2.53 |
$11,250 |
I/I |
4,455 |
20,339 |
|
- |
|
597 Records found
|
|
Page 19 of 24 |
|
|
0.15 (0.58%) 
